ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022 ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022 LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces enrollment completed in the […]
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand starting […]
Study Supports Ongoing Phase 3 Program and Planned NDA Submission LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces ensifentrine met all safety objectives in a thorough QT (“TQT”) study designed to evaluate effects, if any, of […]
Are you sitting comfortably? Do you notice your breathing, all nice and easy? Now, try taking a straw and breathing just through that. Not quite so easy is it?
